Drugs / Acetylated and Butyrylated High Amylose Maize Starch
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04114357 | Jun 2020 → Jun 2023 | type 1 diabetes mellitus | Indiana University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Acetylated and Butyrylated High Amylose Maize Starch | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04114357 ↗ |
| Known as | HAMS-AB | “Additionally, a recent study testing an acetylated and butyrylated form of HAMS (HAMS-AB) that further increases SCFA production prevented T1D in a rodent model without adverse...” PMID 37626387 ↗ Aug 2023 |
| Modality | Other / unclassified | “The prebiotic high amylose maize starch (HAMS) alters the gut microbiome profile and metabolites favorably with an increase in bacteria producing short chain fatty acids...” PMID 37626387 ↗ Aug 2023 |
| Route | Oral | “Participants will be instructed to consume HAMS-AB in two divided doses at breakfast and dinner for 4 weeks” NCT04114357 ↗ |